Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Oleclumab in Muscle-Invasive Bladder Cancer (BLASST-2)
NCT03773666Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2019
- Primary completion
- Feb 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of oleclumab in Muscle Invasive Bladder Cancer (MIBC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose-Limiting Toxicity. Started Feb 2019; status: completed.
02
Drugs
oleclumab
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT03773666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773666.